Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | — |
The patient experienced vomiting after taking a second dose of Vivotif, the capsule was present in the vomit; Case reference number US-BN-2025-001176 is a spontaneous case initially received from a pharmacist via Communication (reference number: USBAV25-1671) on 09-Jul-2025 and concerns a patient of unspecified age and gender. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown), at an unknown dose, route, or site of administration, for an unknown indication. On an unspecified date, unknown time after the first dose, the patient took the second dose of Vivotif (batch number: unknown), at an unknown dose, route, or site of administration. On an unspecified date, also reported as four hours after the patient took the second dose of Vivotif, the patient experienced vomiting, and the capsule was present in the vomit. At the time of the initial report, it was unknown if the patient recovered from the event 'vomiting of medication'. The reporter did not provide a seriousness and causality assessment for the event 'vomiting of medication'. No further information was provided.; Reporter's Comments: A patient of unspecified age and gender experienced a non-serious event of vomiting, and the capsule was present in the vomit, on an unspecified date, also reported as four hours after the patient took the second dose of Vivotif for an unknown indication. Vomiting is listed and expected for Vivotif per CCDS v8 and USPI. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering implied temporal relationship, known vaccine safety profile and since the contributory role of the suspect vaccine cannot be excluded, the reported event has been considered as related to Vivotif. This case is considered as non-serious.; Sender's Comments: A patient of unspecified age and gender experienced a non-serious event of vomiting, and the capsule was present in the vomit, on an unspecified date, also reported as four hours after the patient took the second dose of Vivotif for an unknown indication. Vomiting is listed and expected for Vivotif per CCDS v8 and USPI. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering implied temporal relationship, known vaccine safety profile and since the contributory role of the suspect vaccine cannot be excluded, the reported event has been considered as related to Vivotif. This case is considered as non-serious.
Comments: NONE